AndrewJohnArmstrongMDScM, FACP

Genitourinary Oncology, Hematologic Oncology

Professor of Medicine, Surgery, Pharmacology and Cancer Biology. Director of Research, Duke Cancer Institute’s Center for Prostate and Urologic Cancers, Member of the Duke Cancer Institute

Join to view full profile

Dr. Armstrong is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Armstrong's full profile

Already have an account?

Office
4101 N Roxboro St
Durham, NC 27704
Phone+1 919-684-8111

Fax+1 919-613-3900

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 2000 - 2003
University of Virginia School of MedicineClass of 2000

Certifications & Licensure

NC State Medical License 2006 - 2026
MD State Medical License 2003 - 2006
PA State Medical License 2001 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Alpha Omega Alpha member AOA

Clinical Trials

Multimodality Phase II Study in Prostate Cancer Start of enrollment: 2008 Dec 01
Terminated
Phase 2
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer Start of enrollment: 2009 Jul 01
Terminated
Phase 2
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Sep 01
Completed
Phase 2
Pazopanib, Docetaxel, Prednisone Prostate Start of enrollment: 2011 Jun 01
Completed
Phase 1
BKM120 in Metastatic Castration-resistant Prostate Cancer Start of enrollment: 2011 Aug 01
Terminated
Phase 2
The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 1
Prostate Cancer Circulating Tumor Cells Based on Epithelial-Mesenchymal Transition Biology Start of enrollment: 2012 May 01
Withdrawn
Not Applicable
Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method Start of enrollment: 2011 Nov 01
Completed
Not Applicable
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM) Start of enrollment: 2014 Apr 01
Completed
Phase 2
Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET) Start of enrollment: 2014 Mar 01
Completed
Not Applicable
Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2015 May 06
Completed
Early Phase 1
Join now to see all

Publications & Presentations

PubMed

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-9...
Daniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara, Ernesto Korbenfeld, Rustem Gafanov
Journal of Clinical Oncology. 2025-03-05
Evaluation of ChatGPT as a Reliable Source of Medical Information on Prostate Cancer for Patients: Global Comparative Survey of Medical Oncologists and Urologists.
Arnulf Stenzl, Andrew J Armstrong, Eamonn Rogers, Dany Habr, Jochen Walz
Urology Practice. 2025-03-01
High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes.
Marina N Sharifi, Jamie M Sperger, Amy K Taylor, Katharine E Tippins, Shannon R Reese
Cancer Discovery. 2025-02-06

Lectures

ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).
2019 ASCO Annual Meeting - 6/1/2019
The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treat...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

New Blood Test Predicts Prognosis for Advanced Prostate Cancer PatientsDecember 11th, 2024
Immune Sensitivity Links Race and Survival After Prostate Cancer ImmunotherapyOctober 17th, 2024
Prostate Cancer Treatment Challenge: Which Drugs to Use FirstSeptember 9th, 2024
Join now to see all